MedTrace Logo

One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

NCT00748566 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2021-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.

Conditions

  • Schizophrenia and Disorders With Psychotic Features

Interventions

DRUG

Ziprasidone HCL (oral)

Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00748566 on ClinicalTrials.gov